Abnormal activation of neddylation modification and dysregulated energy metabolism are frequently seen in many types of cancer cells. Whether and how neddylation modification affects cellular metabolism remains largely unknown. Here we showed that MLN4924, a small molecule inhibitor of neddylation modification, induces mitochondrial fission-to-fusion conversion in breast cancer cells via inhibiting ubiquitylation and degradation of fusionpromoting protein mitofusin (MFN1) by SCF b-TrCP E3 ligase and blocking the mitochondrial translocation of fusion-inhibiting protein DRP1. Importantly, MLN4924-induced mitochondrial fusion is independent of cell cycle progression, but confers cellular survival. The Mass-Spectrometry-based metabolic profiling and mitochondrial functional assays reveal that MLN4924 inhibits TCA cycle, but promotes mitochondrial OXPHOS. MLN4924 also increases glycolysis by activating PKM2 via promoting its tetramerization. Biologically, MLN4924 coupled with OXPHOS inhibitor metformin, or glycolysis inhibitor shikonin, significantly inhibits cancer cell growth both in vitro and in vivo. Together, our study links neddylation modification and energy metabolism, and provides sound strategies for effective combinational cancer therapies.
Introduction
Energy is the primary limiting factor for growth and reproduction of all biological systems and it is mainly funneled through mitochondrial oxidative phosphorylation system (OXPHOS) and glycolysis (1) . Cancer cells are capable of reprogram their energy metabolism to adapt to changes in energetic demands (2) . Thus, metabolic reprogramming is a hallmark of cancer to support abnormal growth and survival of malignant cells with sufficient levels of energy and building blocks (3, 4) . A better understanding of cancer energy metabolism has significant implications for cancer pathophysiology and for potential therapeutic interventions (5, 6) .
Mitochondria are essential hubs of bioenergetics (7) . Moreover, as highly dynamic organelles, mitochondria constantly change their morphology between elongated interconnected networks and fragmented shapes by fusion and fission, depending on their physiological and cellular conditions (8) . The fine-tuned mitochondrial fusion and fission dynamics are crucial to maintain mitochondrial function and cellular metabolic reprogramming (9) . Consequently, dysregulated mitochondrial dynamics, particularly a switch towards fission status which causes excess mitochondrial fragmentation, contribute to tumorigenesis (10) . In addition, many cancer cells favors energy through high rate of aerobic glycolysis by enhancing glucose consumption, also known as Warburg effect (11) . The increased glycolysis enables cancer cells to suppress apoptotic signaling and drives their growth and proliferation (12) . Pyruvate kinase (PK) catalyzes the last irreversible step in glycolysis and mediates the conversion of phosphoenolpyruvate (PEP) to pyruvate, thus affecting glycolytic rate. Nowadays, the M2 isoform of pyruvate kinase (PKM2), one splice variant encoded by PKM gene, is the major form of PK in cancer cells and has been found to play an important role in cancer Warburg effect (12, 13) . Recently, accumulating evidence suggests that oncogenes and tumor suppressor genes in cancerdriving pathways reprogram energy metabolism via mediating mitochondrial dynamics or PKM2 activity (10, 14) .
Protein neddylation, one type of posttranslational modifications that regulates protein function and stabilization, is catalyzed by an E1 NEDD8-activating enzyme (NAE), one of two E2 neddylation conjugation enzymes, and one of several E3 neddylation ligases (15) . Cullin family proteins, the scaffold component of cullin-RING-ligase (CRL), have been characterized as physiological substrates of neddylation . Neddylation of Cullin activates CRLs, the largest family of E3 ubiquitin ligases, which are responsible for the degradation of about 20% cellular proteins, thus timely and precisely regulating many biological processes (15) . To date, CRL1, also known as SCF (SKP1-Cullin 1-F-box protein), is the best studied member of CRLs (16) .
SCF E3 ligase consists of adaptor protein SKP1, Cullin 1, RING protein RBX1, and Fbox receptor protein, which determines the substrate specificity (16) . β-TrCP (β-transducin repeat-containing protein), one of the best characterized F-box proteins, regulates many cellular processes by targeting diverse substrates (17) .
Accumulated experimental data have clearly demonstrated that the process of protein neddylation modification is over-activated in many human cancers (15) .
MLN4924, also known as pevonedistat, is the first-in-class inhibitor of NAE, thus inhibiting the entire neddylation modification (18) . Numerous in vitro and in vivo preclinical studies have showed that MLN4924 has attractive suppressing activity against a variety of human cancer cells (15, 18) . Reported mechanisms of MLN4924 anti-cancer action include triggering DNA damage response, non-homologous ending joining repair, DNA re-replication stress, and oxidative stress at the biochemical levels, and inducing cell cycle arrest, apoptosis, autophagy, senescence at the cellular levels (18) (19) (20) . To date, whether and how neddylation modification regulates energy metabolism remain largely unknown, although few studies have shown that blockage of neddylation disrupts nucleotide metabolism and affects mitochondrial function through oxidation stress in human acute myeloid leukemia and ovarian cancer cells (21) (22) (23) .
Here, we showed that energy metabolism is largely altered after neddylation blockage by MLN4924. Specifically, MLN4924 caused accumulation of MFN1 via inhibiting its ubiquitylation and degradation by SCF β-TrCP E3 ligase, and block mitochondrial translocation of DRP1 to induce mitochondrial fission-to-fusion conversion. MLN4924 also impaired mitochondrial functions, but increased OXPHOS.
In addition, MLN4924 promoted cellular glycolysis by activating PKM2 via inducing its tetramerization. Biologically, combination of MLN4924 with a clinical-used OXPHOS inhibitor metformin, or a glycolytic inhibitor shikonin, significantly enhanced killing of breast cancer cells in both in vitro culture models and two in vivo xenograft tumor models. This is the first report, to the best of our knowledge, demonstrating mechanistically how neddylation modification regulates energy metabolism. Our study also has translational value by providing a sound rationale for future clinical combination of MLN4924 with inhibitors of OXPHOS or glycolysis to enhance efficacy of cancer therapy.
Results

Blockage of neddylation induces mitochondrial fission-to-fusion conversion
We and the others have previously shown that MLN4924 could trigger oxidative stress (21, 22) . Given that mitochondrion is the major subcellular organelle that regulates cellular oxidation, we examined potential effect of MLN4924 on mitochondrial dynamics. We first transfected two breast cell lines MDA-MB-231 and SK-BR-3 with mito-DS-Red to monitor mitochondrial morphology (24 treatment, mitochondria changed to an elongated tubular fusion shape from fission sphere appearance ( Figure 1E ).
To exclude potential off-target effect of MLN4924 on mitochondrial dynamics, we used siRNA-based approach to knock-down NAEβ ( Figure 1F ), a catalytic subunit of NAE (25) , to which MLN4924 binds and inhibits (18, 26 Taken together, these results indicate that increase in fusion-promoting proteins, particularly MFN1, and decrease mitochondrial fusion-suppressing protein DRP1 are associated with fission-to-fusion conversion by MLN4924.
MFN1, MFN2 and DRP1 are causally responsible for fusion conversion
We next determined whether alterations in the levels of MFN1/2 and DRP1 are causally related to observed fission-to-fusion conversion. MFN1 or MFN2 were individually knocked down via two independent siRNAs (Figures 2F and 2G, S2F and S2G). MFN1 knockdown completely rescued MLN4924-induced fission-to-fusion conversion, whereas MFN2 knockdown caused a ~70% of rescue ( Figures 2H and S2H) .
Similarly, ectopic expression of DRP1 showed a 50% of rescue of MLN4924-induced mitochondrial fusion ( Figures 2I and S2I) , while showing no effect on increased MFN1
and MFN2 levels by MLN4924 ( Figures 2J and S2J ). Collectively, these data indicate that increased MFN1 as well as MFN2, and decreased mitochondrial DRP1 are all causally responsible for MLN4924-induced mitochondrial fusion with MFN1 playing a dominant role.
MLN4924-induced fusion is not due to G2/M arrest, but enhances cell survival
It has been previously reported that mitochondrial fusion is associated with cell cycle arrest, whereas MLN4924 indeed induced G2/M arrest in both breast cancer lines (30, 31) . We, therefore, determined whether observed mitochondrial fusion is 
SCF β-TrCP E3 ligase mediates MFN1 ubiquitylation and degradation
To elucidate the mechanism(s) by which MLN4924 increased the levels of MFN1/2, we first focused on Parkin, a mitochondrial E3 known to be a neddylation substrate that promotes MFN1/2 ubiquitylation and degradation (32, 33) . We used Parkin-null HeLa cells (34) and found that MLN4924 remained active to cause a dosedependent increase of MFN1, with minor effect on MFN2 ( Figure S3A ). Thus, involvement of Parkin was excluded for MLN4924-induced accumulation of MFN1/2.
We next turned our attention to CRL/SCF β-TrCP as a potential E3 for targeted ubiquitylation and degradation of MFN1 after identifying an evolutionarily conserved β-TrCP dragon motif ( 85 SSGKSS 90 ) on MFN1 ( Figure S3B ). Given MFN1 is a mitochondrial protein, we first determined whether the components of SCF are also localized in mitochondria. Indeed, cullin-1, β-TrCP1, and RBX1 were all detected in both cytosolic and mitochondrial fractions with cullin-1 neddylation being inhibited by MLN4924 ( Figures 3A and S3C ). We then systematically examined whether MFN1
was a bona fide substrate of the SCF β-TrCP E3 ligase. First, we found that a) exogenously 
Global metabolic profiling identifies alterations in energy metabolism
We next used Mass-Spectrometry-based metabolic profiling to investigate the overall effect of neddylation inhibition on cell metabolism at global levels. MDA-MB-231 cells were treated with MLN4924 in three independent experiments, and an Thus, neddylation blockage altered global metabolic profiling and energy metabolism by modulating glycolysis and OXPHOS.
MLN4924 inhibits multiple mitochondria functions
Having established that neddylation blockage affects both mitochondrial morphology and TCA cycle, whereas mitochondrial dynamics is closely associated with mitochondrial functions and cellular metabolic operations (9), we next determined potential effect of MLN4924 precisely on mitochondrial integrity and functions. First, we measured the mitochondrial oxygen consumption rate (OCR) using Seahorse XF96
Analyzer ( 
Enhanced cancer cell killing by co-targeting neddylation and OXPHOS or glycolysis
Fused mitochondria are usually considered as energetically active through OXPHOS, which are commonly associated with cytoprotective functions (9 glycolysis, and neddylation inhibitor should, therefore, be used in combination with inhibitors of OXPHOS or glycolysis to significantly enhance its anti-cancer efficacy.
Our study provides a sound strategy for mechanism-based combinational target therapy.
Discussion
Abnormal energy metabolism is one of well-characterized tumor hallmarks and therapeutic targeting of such abnormality draws an increasing attention (3, 38) . Here we reported an unexpected finding that neddylation blockage by its inhibitor MLN4924
induced mitochondrial fission-to-fusion conversion, altered mitochondrial function, and promoted glycolysis, and that therapeutic combination of MLN4924 with OXPHOS inhibitor metformin, or glycolysis inhibitor shikonin, significantly increase anti-cancer efficacy in both in vitro and in vivo models.
Mitochondrial fusion and fission dynamics is a complicated process that is Finally, our MFN1 knockdown-based rescue experiments revealed that MFN1 is responsible for MLN4924-induced fission-to-fusion conversion, partially responsible for altered mitochondrial functions, but had no effect on altered glycolysis.
The metabolic shift from decreased mitochondrial functions to increased glycolysis has been adopted by cancer cells to cope with metabolic need (12), termed as the Warburg effect (11, 14) . Here we made a novel and unexpected observation that neddylation blockage can induce this Warburg phenotype ( Figure 6 ). Mechanistically, we focused on PKM2, a key enzyme whose activation is known to promote glycolysis (12, 13) . We found that MLN4924-induced PK activity is solely due to PKM2 activation.
We also showed that PKM2 activation by MLN4924 is not due to increased protein level, but due to induced formation of tetrameric form, which was reported as the most active form of the enzyme (12) . Our in vitro PKM2 activity assay further confirmed MLN4924 activation of PKM2, which is to an extent slightly better than SAICAR, Figure   8 ). Our study, therefore, demonstrated that energy metabolism is subjected to neddylation regulation, and also provides a proof-of-concept evidence for rational drug combinations to increase efficacy of cancer therapy.
Materials and Methods
Cell culture and transfection
Human with 10% fetal bovine serum (Gibco) and incubated at 5% CO2 incubator (Thermo) at 37℃ and 95% humidity.
Cells were transfected with various plasmids using Lipofectamine 3000
Transfection Reagent or with si-RNA oligonucleotides by Lipofectamine RNAiMAX Transfection Reagent, according to the manufacturer's instructions, respectively.
Antibodies and reagents
The following antibodies were used: CUL-1 (Santa Cruz, sc-11384); MFN1 
Electron microscopy
Cells were fixed with 2.5% glutaraldehyde overnight at 4℃. After washing in 100 mM phosphate buffer (pH 7.4), cells were post-fixed for 1.5h at room temperature in 1% osmium tetroxide (OSO4), followed by washing with phosphate buffer, 
Immunoblots and Immunoprecipitation
For direct immunoblot analysis, the proteins were lysed from cells and quantified with the Bio-Rad protein assay kit (Bio-Rad laboratories, 500-0002EDU).
The denatured proteins were subjected to SDS-PAGE, transferred to PVDF membranes, followed by immunoblot analysis with various antibodies.
For immunoprecipation analysis, transfected cell lysates were incubated with bead-conjugated Flag or HA in a rotating incubator overnight at 4 ℃ . The immunoprecipates were washed with lysis buffer and detected by immunoblot analysis.
Protein half-life measurement
Cells were transfected with indicated plasmids or siRNA against MFN1 for 48 h, then treated with 50 μg/ml CHX for various time points and collected for immunoblot.
The band density was quantified using ImageJ software.
The in vivo ubiquitylation assay
HEK293 cells were transfected with constructs encoding β-TrCP1, HA-his-Ub, MFN1 or MFN1 S85/86/90A mutant, along with empty construct or β-TrCP1△F controls. Forty-eight hours after transfection, cells were treated with MG132 (20 μM) for 6 h and then lysed with denatured buffer containing 6 M Guanidine, as described previously (53) . MFN1-ploy-Ub was purified by Ni-bead pull-down and detected by immunoblot using MFN1 Ab.
FACS (fluorescence-activated cell sorting) analysis
Cells were harvested and fixed with 75% ethanol overnight, then washed twice with phosphate buffered saline (PBS) and suspended in PI/RNase Staining Buffer (BD Pharmingen) for 15 min in the dark. The samples were analyzed using flow cytometry (FC500 MPL, Beckman Coulter) for cell cycle distribution.
Cell viability and clonogenic survival assays
Cells were harvested, suspended in PBS and mixed with 0.4% solution of trypan blue (Sigma). Viable cells were counted. For clonogenic survival assay, 500 cells were seeded in 3-cm dish, followed by incubation for 10 days with drug-containing fresh medium. The colonies were fixed, stained and counted under an inverted microscope.
Colonies with 50 cells or more were counted.
Metabolic profiling analysis
The untargeted metabolic profiling analysis was performed on XporeMET platform (Metabo-Profile, Shanghai, China) and sample preparation procedures are referred in their previously published methods (54) .
Mitochondria isolation
Cell mitochondrial isolation kit was purchased from Beyotime (C3601) and the assay was performed according to manufacturer's instruction.
Measurement of the mitochondrial membrane potential
Mitochondrial membrane potential was assessed with Mitochondria Staining Kit (JC-1) (Multisciences, 125T). In brief, cells were collected in staining buffer and JC-1 was added for 30 min at 37°C, 5% CO2. Alternatively, cells were preincubated with protonophore uncoupler carbonyl cyanide 3-chlorophenylhydrazone (CCCP) for 5 min at 37°C, 5% CO2 prior to staining with JC-1. Sample fluorescence was measured by flow cytometry.
Measurement of intracellular ATP levels
The ATP levels in cells were measured using ATP-lite Luminescence Assay Kit (PerkinElmer) according to the manufacture's protocol and the ATP level was normalized to the protein content.
Detection of mitochondrial copy number
Total cellular DNA was isolated using the Genomic DNA Extraction Kit (Takara, 9765). Quantitative real-time RT-PCR assay was used to detect mitochondrial DNA (mtDNA) number. mtDNA levels were detected using primers for mtDNA-encoded human gene 16S rRNA (5'-GCACACCCGTCTATGTAGCAAA-3' and 5'-GATTTAGAGGGTTCTGTGGGCA-3'), and nuclear DNA levels was detected using primers for nuclear-encoded human β-globin (5'-AGAAACTGGGCATGTGGA GACA-3' and 5'-ATGAGCCTTCACCTTAGGGTTG-3'). mtDNA was normalized to nuclear DNA.
Measurement of mitochondrial ROS
ROS generation by mitochondria in living cells was analyzed the mitochondrial superoxide indicator Mitosox Red (Invitrogen, M36008). Samples were analyzed by flow cytometry with an excitation at 510 nm and emission at 580 nm.
Measurement of OCR and ECAR
The OCR and ECAR were measured using XF96 Analyzer (Seahorse sequentially. After measurement of OCR and ECAR, data were normalized to the cell number in each well.
Measurement of glucose metabolism
Cells were seeded onto culture dishes and treatment with various concentrations of MLN4924 for indicated time periods. The media were then collected to measure the concentration of glucose, pyruvate and lactate. Glucose levels were detected using a glucose assay kit (Shanghai Rongsheng Biotech, China). Glucose consumption was calculated by deducting the remaining glucose in the medium from the original glucose in the media. Pyruvate and lactate production were measured using a pyruvate assay kit and lactate assay kit (Nanjing Jiancheng Bioengineering Institute, China), respectively.
Pyruvate kinase activity was detected using a pyruvate kinase kit (Solarbio, BC0545, China). All values were normalized according to cell number.
The in vitro PKM2 activity assay
Briefly, pCold I PKM2 was transformed into BL21 Codonplus RIL (DE3) cells.
PKM2 expression was induced by IPTG and cell pellets were suspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 7.4) supplemented with cocktail. Cells were lysed by sonication, and cell debris was removed by centrifugation.
Supernatant was incubated with Ni-NAT agarose (Qiagen) for 4 h at 4°C. PKM2 protein was recovered by centrifugation, eluted with elution buffer ( 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 7.4 ), and the purity was verified by PAGE. The in vitro pyruvate kinase activity was measured using a pyruvate kinase kit (Solarbio, BC0545, China) and 2.5 μM PKM2 (elution fractions 1 and 2) was used alone or with different concentrations of MLN4924 or SAICAR.
Crosslinking assay
Cells were treated with various concentrations of MLN4924 for 24 hrs, and 
Statistical analyses
All experiments were repeated at least three independent times and the representative data was presented as means ± standard deviation (SD). Linear mixed effects model was used to compare tumor growth rates among the control and treatment groups based on log-transformed tumor volumes measured over time. The model includes a random intercept and a random slope to allow each tumor has its own growth profile. The fit of the model was visually checked by various residual plots. Additionally, we compared tumor volume doubling times among each group. Tumor volume doubling was determined for each xenograft by identifying the earliest day on which it was at least twice as large as on the first day of treatment. A cubic smoothing spline was used to obtain the exact time of doubling. Then the doubling times were estimated using Kaplan-Meier methods and compared among the groups using Log-rank tests to generate survival probability. One-way or two-way analysis of variance (ANOVA) was performed to determine the significance among the groups. Among all the data sets, P values less than 0.05 were considered significant and are denoted as *P<0.05, **P<0.01.
Study approval
All animal studies were approved, and conducted in accordance with the guidelines established by the Committee on Use and Care of Animals at the University of Michigan (UM approval number is RPO00006919). (C) MDA-MB-231 cells were treated with 300 nM MLN4924 for 24h and mitochondria were isolated. Cytoplasmic (CY) and mitochondrial (MT) fractions were subjected to Western Blotting with indicated antibodies. α-tubulin and Tom20 were served as loading marker for cytoplasmic and mitochondrial fractions, respectively. SE: short exposure; LE: long exposure. (D) The DRP1 expression levels (C) in cytosol and mitochondria were normalized to α-tubulin and Tom20, respectively. Results are shown as mean ± SD (n=3). **P<0.01, one-way ANOVA. (E) The phosphorylated DRP1 S616 levels (C) were normalized by total DRP1 levels in indicated cellular fraction (mean ± SD, n=3). **P<0.01, one-way ANOVA. (F, G) MDA-MB-231 cells were transfected with indicated siRNAs against MFN1 or MFN2.Forty-eight hrs posttransfection, cells were harvested and subjected to Western Blotting with indicated antibodies. *designates a non-specific band. (H, I) MDA-MB-231 cells were transfected with indicated siRNAs (H) or plasmids expressing HA-vector (I) for 24h, and then treated with 300 nM MLN4924 for another 24h, cells were then stained with MitoTracker Red, and mitochondrial morphology was photographed by confocal microscope. The interconnected filamental mitochondria are quantified (mean ± SD, n=3). *P<0.05, **P<0.01, one-way ANOVA. (J) MDA-MB-231 cells were transfected with HA-vector or HA-DRP1 for 24h, followed by treatment with various concentrations MLN4924 for another 24h before being subjected to Western Blotting using indicated antibodies. *designates a nonspecific band. (K) MDA-MB-231 cells were transfected with indicated siRNAs against MFN1 or MFN2 and plasmids expressing HA-vector for 24h, treated with MLN4924 at 100 or 300 nM, followed by FACS analysis after 24h. Cells at the G2/M phase were plotted (mean ± SD, n=3). (L) MDA-MB-231 cells were transfected with either si-NC, si-MFN1#2 or si-MFN2#2 for 24h, then treated with MLN4924 at 100 or 300 nM, followed by trypan blue exclusion assay for cell viability after 48h (mean ± SD, n=3). *P<0.05, **P<0.01, oneway ANOVA. (M) MDA-MB-231 cells were transfected with HA-vector and HA-DRP1 for 24h, then treated with MLN4924 at 100 or 300 nM, followed by trypan blue exclusion assay for cell viability after 48h (mean ± SD, n=3). *P<0.05, **P<0.01, one-way ANOVA. 
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